Adaptive Biotechnologies Corporation
Last updated September 27, 2026
Organization details
- Legal name
- Adaptive Biotechnologies Corporation
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ADPT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001478320
Board of directors
-
Chad M. Robins · Director · CEO and ChairmanSince 2023
-
Katey Einterz Owen · DirectorSince 2023
-
Kevin T. Conroy · DirectorSince 2023
-
Leslie Trigg · DirectorSince 2023
-
Michael J. Pellini · DirectorSince 2023
-
Michelle Renee Griffin · DirectorSince 2023
-
Peter M. Neupert · DirectorSince 2023
-
Robert Hershberg · DirectorSince 2023
Chief executives
Chad M. Robins
· CEO and Chairman
Dates unknown
Board connections
4 of this board's directors also sit on 6 other boards.
- via Kevin T. Conroy
- via Robert Hershberg
- via Peter M. Neupert
- via Peter M. Neupert
- via Leslie Trigg
- via Robert Hershberg
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 24, 2025 | ROBINS HARLAN S Officer (Chief Scientific Officer) | Option exercise | +1,698 | $6.32 | $10,731 |
| Mar 24, 2025 | ROBINS HARLAN S Officer (Chief Scientific Officer) | Open-market sale | −1,698 | $9.00 | $15,282 |
| Mar 14, 2025 | PISKEL KYLE Officer (Chief Financial Officer) | Option exercise | +2,500 | $6.32 | $15,800 |
| Mar 13, 2025 | Michelle Renee Griffin Director | Open-market sale | −36,291 | $7.19 | $260,932 |
| Mar 12, 2025 | Robert Hershberg Director | Open-market sale | −53,000 | $7.59 | $402,270 |
| Mar 10, 2025 | Peter M. Neupert Director | Option exercise | +50,000 | $4.07 | $203,500 |
| Mar 10, 2025 | Peter M. Neupert Director | Open-market sale | −10,000 | $7.05 | $70,500 |
| Mar 6, 2025 | Michelle Renee Griffin Director | Open-market sale | −15,664 | $7.94 | $124,372 |
| Mar 6, 2025 | Chad M. Robins Director, Officer (CEO and Chairman) | Open-market sale | −102,218 | $7.64 | $780,946 |
| Mar 5, 2025 | LO FRANCIS Officer (Chief People Officer) | Open-market sale | −7,085 | $6.98 | $49,453 |
| Mar 5, 2025 | BOBULSKY SUSAN Officer (Chief Commercial Officer, MRD) | Open-market sale | −26,023 | $6.98 | $181,641 |
| Mar 5, 2025 | BENZENO SHARON Officer (Chief Commercial Ofc Imm Med) | Open-market sale | −41,600 | $6.98 | $290,368 |
| Mar 5, 2025 | PISKEL KYLE Officer (Chief Financial Officer) | Open-market sale | −3,103 | $6.97 | $21,628 |
| Mar 5, 2025 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −40,044 | $6.98 | $279,507 |
| Mar 5, 2025 | ROBINS HARLAN S Officer (Chief Scientific Officer) | Open-market sale | −40,603 | $6.98 | $283,409 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.